The Motley Fool
12 Nov 2025, 19:00 UTC · 45w ago
Verdict
Headline takes no side. We score LLY +0.60 across three claims — strongly bullish.
+0.60strongly bullish
More positive than 73% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Eli Lilly's GLP-1 drug received independent approval to treat obstructive sleep apnea without requiring CPAP machines.
More negative than 99% of claims this week
Weight loss from GLP-1 treatments may eliminate the need for breathing assistance devices for the 70-90% of sleep apnea sufferers whose condition is driven by obesity.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More negative than 95% of claims this week
ResMed is seeing a short-term increase in CPAP prescriptions as patients seeking GLP-1 treatments also address obesity-related comorbidities.
More positive than 63% of claims this week
Which stocks this story touches
More positive than 73% of ticker scores this week
Its GLP-1 drug received approval to treat obstructive sleep apnea, directly challenging competitors' business models.
More negative than 74% of ticker scores this week
The company faces long-term existential threats and potential market disruption from GLP-1 weight loss drugs.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
3h ago
+16.3%
Price agrees with the score
$1149.77 vs $988.62 close before publication (Nov 11) · not market-adjusted
LLY chart →
